Catalio BH SPV, LLC has reported substantial changes in its stock ownership of Iambic Therapeutics, Inc. This update is crucial as it reflects a shift in investment strategy and ownership structure that could have significant implications for the company and the broader life sciences sector.
Iambic Therapeutics, Inc. is classified under the SIC code for Biological Products (No Diagnostic Substances) [2836]. This classification indicates that the company operates within a critical area of the life sciences industry, focusing on developing biological products that do not include diagnostic substances.
Details from the Filing
The SEC filing, accession number 0001958125-26-000011, reveals that Catalio BH SPV, LLC, along with its affiliates, has undergone significant ownership changes. Specifically, the filing details the acquisition of 1,995,749 shares of common stock, 1,458,290 shares, and 742,546 shares, all acquired on October 16, 2026. Additionally, the report notes the conversion of various series of preferred stock into common stock, including Series A, B, B-3, B-4, and convertible promissory notes, which were also converted into common stock.
Impact on Stakeholders
This ownership change may affect various stakeholders, including investors, company management, and competitors. The filing indicates that the reporting entities, such as Catalio Capital Management, LP, and its associated funds, are no longer subject to Section 16 reporting requirements due to their beneficial ownership falling below ten percent. This could alter the way these entities interact with Iambic Therapeutics moving forward.
What's Next?
The filing does not specify what actions will follow these changes in ownership. However, it sets the stage for potential shifts in governance and strategy at Iambic Therapeutics, as well as adjustments in the competitive landscape of the life sciences industry.